9-ING-41 in Patients With Advanced Cancers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Epistemonikos ID: c57d5fb51d56161fd15ac1b0fd70b16eee23d25c
First added on: May 21, 2024